BioSpace News Archive

Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, announced that Daniel Menichella has been appointed President and Chief Executive Officer and a member of the company’s Board of Directors, effective October 13, 2020. Mr. Menichella succeeds Alison Lawton, who stepped down to attend to a family health matter but

Poster Presentation to Highlight Preclinical Data on RP-L401 for Infantile Malignant Osteopetrosis

ITOCO INC. has successfully completed and deployed the blockchain portion of its patent-pending Immutable Virus Test Result Verification System to the Ethereum Ropsten test network.

According to a recent study from the Centers for Disease Control and Prevention, 160,000 children miss school every day across the U.S. out of fear of being bullied.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, a

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Company’s IGNITE DMD Phase I/II clinical trial.

Provention Bio, Inc. (Nasdaq:PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, yesterday launched a national effort to redefine patient care in type 1 diabetes (T1D) with t

Aegle Therapeutics Corporation today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AGLE-102™ for the treatment of patients with dystrophic epidermolysis bullosa (“DEB”), a rare genetic pediatric skin blistering disorder. AGLE-102 is an extracellular vesicle (“EV”) therapy that deliv

Editas Medicine, Inc., a leading genome editing company, announced that management will participate in the following upcoming investor conference:

X4 Pharmaceuticals, Inc. announced the expansion of its board of directors with the appointment of Alison Lawton, a biopharmaceutical industry veteran with more than 30 years of experience in a wide range of senior executive and operational roles.